Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for

LivaNova to Announce Third-Quarter 2023 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Third-Quarter 2023 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time

ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The

Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

NanoString Comments on Unified Patent Court Order: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Comments on Unified Patent Court Order


NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on today’s order from the European Unified Patent Court

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areatahttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata


Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areatahttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata


Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analystshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analystshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The

Inogen Completes Acquisition of Physio-Assist: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Completes Acquisition of Physio-Assist


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has completed the acquisition of Physio-Assist

Board Announcement
Board Announcement
Board Announcement
Transgene Announces Upcoming Investor Meetings: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Announces Upcoming Investor Meetings


Regulatory News:



TRANSGENE (Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that Management will participate in

STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, will host Vision 2026, the Company’s investor day, at the Nasdaq MarketSite

BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development

EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
EQS-News: Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
Premier, Inc. Realigns Leadership Team and Promotes Key Executives to Accelerate Innovation and Profitable Growth: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Realigns Leadership Team and Promotes Key Executives to Accelerate Innovation and Profitable Growth


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced three executive promotions that strategically position the

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the J.P

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience:
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience


Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced the availability of its Dexcom ONE real-time CGM sensor via

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced the availability of its Dexcom ONE real-time CGM sensor via